IDEXX Laboratories Inc (IDXX) stock

IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 19/309% above fair value

$551.21−24.77 (-4.30%)

Close on Oct 30, 2026Market cap $43.42BP/E 38.8Yield –

Earnings

IDEXX Laboratories's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Nov 2, 2026

Q3 FY2026 · estimated, before the open

Revenue, Q2 FY2026

–

Comparable EPS, Q2 FY2026

$4.07

$3.50 a year earlier

Latest guidance

Raised

Aug 4, 2026 · 12 items

Quarterly results

Revenue and earnings per share from each of IDEXX Laboratories's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q3 FY2026ended Sep 30, 2026	Nov 2, 2026Expected	–	–	–	–	–
Q2 FY2026ended Jun 30, 2026	Aug 4, 2026before the open	–	–	$4.27	$4.07	Release
Q1 FY2026ended Mar 31, 2026	May 5, 2026before the open	$1.14B	+14.3%	$3.47	$3.30	Release
Q4 FY2025ended Dec 31, 2025	Feb 2, 2026before the open	$1.09B	–	$3.08	$2.92	Release
Q3 FY2025ended Sep 30, 2025	Nov 3, 2025before the open	$1.11B	+13.2%	$3.40	$3.22	Release
Q2 FY2025ended Jun 30, 2025	Aug 4, 2025before the open	–	–	$3.63	$3.50	Release
Q1 FY2025ended Mar 31, 2025	May 1, 2025before the open	$998.00M	+3.5%	$2.96	–	Release
Q4 FY2024ended Dec 31, 2024	Feb 3, 2025before the open	–	–	$2.62	$2.53	Release
Q3 FY2024ended Sep 30, 2024	Oct 31, 2024before the open	$976.00M	+6.6%	$2.80	$2.79	Release
Q2 FY2024ended Jun 30, 2024	Aug 6, 2024before the open	$1.00B	+6.4%	$2.44	$3.02	Release
Q1 FY2024ended Mar 31, 2024	May 1, 2024before the open	$964.00M	+7.1%	$2.81	$2.71	Release
Q4 FY2023ended Dec 31, 2023	Feb 5, 2024before the open	$902.00M	+8.8%	$2.32	$2.34	Release
Q3 FY2023ended Sep 30, 2023	Nov 1, 2023before the open	$916.00M	+8.8%	$2.53	$2.50	Release
Q2 FY2023ended Jun 30, 2023	Aug 1, 2023before the open	$944.00M	+9.6%	$2.67	$2.70	Release
Q1 FY2023ended Mar 31, 2023	May 2, 2023before the open	$900.00M	+7.5%	$2.55	$2.60	Release
Q4 FY2022ended Dec 31, 2022	Feb 6, 2023before the open	$829.00M	+3.5%	$2.05	$2.07	Release
Q3 FY2022ended Sep 30, 2022	Nov 1, 2022before the open	$842.00M	+4.0%	$2.15	–	Release
Q2 FY2022ended Jun 30, 2022	Aug 2, 2022before the open	$861.00M	–	$1.56	–	Release
Q1 FY2022ended Mar 31, 2022	May 4, 2022before the open	$837.00M	–	$2.27	$2.24	Release
Q4 FY2021ended Dec 31, 2021	Feb 2, 2022before the open	$801.00M	–	$1.89	$1.83	Release
Q3 FY2021ended Sep 30, 2021	Nov 2, 2021before the open	$810.00M	–	$2.03	$1.96	Release
Q2 FY2021ended Jun 30, 2021	Jul 30, 2021before the open	–	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	May 4, 2021before the open	–	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Feb 2, 2021before the open	–	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Oct 29, 2020before the open	–	–	–	–	Filing
Q2 FY2020ended Jun 30, 2020	Jul 31, 2020before the open	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

IDEXX Laboratories's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Organic growthnon-GAAP	FY2026	+8.5% – +9.7%	+7.7% – +9.7%	Raised	Aug 4, 2026
Reported growth	FY2026	+9.1% – +10.3%	+8.6% – +10.6%	Narrowed	Aug 4, 2026
Reported growthGAAP	FY2026	+7.6% – +9.6%	–	New	Feb 2, 2026
Revenue	FY2026	$4.70B – $4.75B	$4.68B – $4.76B	Narrowed	Aug 4, 2026
RevenueGAAP	FY2026	$4.63B – $4.72B	–	New	Feb 2, 2026
Operating Margin	FY2026	32.3% – 32.5%	32.1% – 32.5%	Raised	Aug 4, 2026
Operating MarginGAAP	FY2026	32% – 32.5%	–	New	Feb 2, 2026
EPSGAAP	FY2026	$14.69 – $14.94	$14.29 – $14.80	Raised	Aug 4, 2026
EPS	FY2026	$14.45 – $14.90	–	New	May 5, 2026
Reported growthGAAP	FY2026	+12% – +14%	+9% – +13%	Raised	Aug 4, 2026
Comparable growthnon-GAAP	FY2026	+13% – +15%	+10% – +14%	Raised	Aug 4, 2026
Free Cash Flow (% of Net Income)non-GAAP	FY2026	85% – 95%	–	New	May 5, 2026
Capital Expenditures	FY2026	$180.00M	$180.00M	Reaffirmed	Aug 4, 2026
CAG Diagnostics Recurring Revenue Growth Organic growthnon-GAAP	FY2026	+8.7% – +10.7%	–	New	May 5, 2026
CAG Diagnostics Recurring Revenue Growth Reported growth	FY2026	+9.6% – +11.6%	–	New	May 5, 2026
Effective tax rate	FY2026	21.1%	21.4%	Lowered	Aug 4, 2026
EPS Comparable growthnon-GAAP	FY2026	+11% – +15%	–	Raised	May 5, 2026
EPS Reported growth	FY2026	+11% – +14%	–	Raised	May 5, 2026
Net interest expense	FY2026	$35.00M	$34.00M	Raised	Aug 4, 2026
Operating Cash Flow (% of Net Income)	FY2026	105% – 115%	–	Raised	May 5, 2026
Reduction in average shares outstanding	FY2026	1% – 2%	–	Lowered	May 5, 2026
Share-based compensation EPS impact	FY2026	$0.19	–	New	May 5, 2026
Share-based compensation tax benefit	FY2026	$15.00M	–	Lowered	May 5, 2026
Share-based compensation tax rate benefit	FY2026	1%	–	Lowered	May 5, 2026

Guidance vs results

The last range IDEXX Laboratories gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	EPS (GAAP)	$12.81 – $13.01	$13.07Σ4Q	Above range

Guidance history

Every forecast IDEXX Laboratories put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Aug 4, 2026	Capital Expenditures	FY2026	$180.00M	Reaffirmed
Aug 4, 2026	Comparable growth	FY2026	+13% – +15%	Raised
Aug 4, 2026	Reported growth	FY2026	+12% – +14%	Raised
Aug 4, 2026	EPS	FY2026	$14.69 – $14.94	Raised
Aug 4, 2026	Operating Margin	FY2026	32.3% – 32.5%	Raised
Aug 4, 2026	Effective tax rate	FY2026	21.1%	Lowered
Aug 4, 2026	Net interest expense	FY2026	$35.00M	Raised
Aug 4, 2026	Reported growth	FY2026	+9.1% – +10.3%	Narrowed
Aug 4, 2026	CAG Diagnostics Recurring Revenue Growth Reported growth	FY2026	+10.1% – +11.3%	Raised
Aug 4, 2026	Organic growth	FY2026	+8.5% – +9.7%	Raised
Aug 4, 2026	CAG Diagnostics Recurring Revenue Growth Organic growth	FY2026	+9.5% – +10.7%	Raised
Aug 4, 2026	Revenue	FY2026	$4.70B – $4.75B	Narrowed
May 5, 2026	Capital Expenditures	FY2026	$180.00M	Reaffirmed
May 5, 2026	EPS	FY2026	$14.45 – $14.90	New
May 5, 2026	Free Cash Flow (% of Net Income)	FY2026	85% – 95%	New
May 5, 2026	Operating Margin	FY2026	32.1% – 32.5%	New
May 5, 2026	Share-based compensation tax rate benefit	FY2026	1%	Lowered
May 5, 2026	Effective tax rate	FY2026	21.4%	Raised
May 5, 2026	Reduction in average shares outstanding	FY2026	1% – 2%	Lowered
May 5, 2026	Operating Cash Flow (% of Net Income)	FY2026	105% – 115%	Raised
May 5, 2026	CAG Diagnostics Recurring Revenue Growth Reported growth	FY2026	+9.6% – +11.6%	New
May 5, 2026	EPS Reported growth	FY2026	+11% – +14%	Raised
May 5, 2026	CAG Diagnostics Recurring Revenue Growth Organic growth	FY2026	+8.7% – +10.7%	New
May 5, 2026	EPS Comparable growth	FY2026	+11% – +15%	Raised
May 5, 2026	Net interest expense	FY2026	$34.00M	Reaffirmed
May 5, 2026	Share-based compensation tax benefit	FY2026	$15.00M	Lowered
May 5, 2026	Share-based compensation EPS impact	FY2026	$0.19	New
May 5, 2026	Reported growth	FY2026	+8.6% – +10.6%	New
May 5, 2026	Organic growth	FY2026	+7.7% – +9.7%	Lowered
May 5, 2026	Revenue	FY2026	$4.68B – $4.76B	New
Feb 2, 2026	Capital Expenditures	FY2026	$180.00M	New
Feb 2, 2026	Comparable growth	FY2026	+10% – +14%	New
Feb 2, 2026	Reported growth	FY2026	+9% – +13%	New
Feb 2, 2026	EPS	FY2026	$14.29 – $14.80	New
Feb 2, 2026	Operating Margin	FY2026	32% – 32.5%	New
Feb 2, 2026	Effective tax rate	FY2026	21.3%	New
Feb 2, 2026	Net interest expense	FY2026	$34.00M	New
Feb 2, 2026	Reported growth	FY2026	+7.6% – +9.6%	New
Feb 2, 2026	CAG Diagnostics Recurring Revenue Growth Reported growth	FY2026	+8.6% – +10.6%	Raised
Feb 2, 2026	Organic growth	FY2026	+7% – +9%	New
Feb 2, 2026	CAG Diagnostics Recurring Revenue Growth Organic growth	FY2026	+8% – +10%	Raised
Feb 2, 2026	Revenue	FY2026	$4.63B – $4.72B	New
Nov 3, 2025	Capital Expenditures	FY2025	$140.00M	Lowered
Nov 3, 2025	EPS	FY2025	$12.81 – $13.01	Raised
Nov 3, 2025	Free Cash Flow (% of Net Income)	FY2025	95% – 100%	Raised
Nov 3, 2025	Operating Margin	FY2025	31.6% – 31.8%	Raised
Nov 3, 2025	Share-based compensation tax rate benefit	FY2025	1.7%	Lowered
Nov 3, 2025	Effective tax rate	FY2025	20.8%	Raised
Nov 3, 2025	Reduction in average shares outstanding	FY2025	2.5% – 3%	Lowered
Nov 3, 2025	Operating Cash Flow (% of Net Income)	FY2025	105% – 115%	Raised
Nov 3, 2025	CAG Diagnostics Recurring Revenue Growth Reported growth	FY2025	+8.3% – +9%	Raised
Nov 3, 2025	EPS Reported growth	FY2025	+20% – +22%	Raised
Nov 3, 2025	CAG Diagnostics Recurring Revenue Growth Organic growth	FY2025	+7.5% – +8.2%	Raised
Nov 3, 2025	EPS Comparable growth	FY2025	+12% – +14%	Raised
Nov 3, 2025	Net interest expense	FY2025	$38.50M	Raised
Nov 3, 2025	Share-based compensation tax benefit	FY2025	$23.00M	Lowered
Nov 3, 2025	Share-based compensation EPS impact	FY2025	$0.28	Raised
Nov 3, 2025	Reported growth	FY2025	+9.6% – +10.3%	Raised
Nov 3, 2025	Organic growth	FY2025	+8.8% – +9.5%	Raised
Nov 3, 2025	Revenue	FY2025	$4.27B – $4.30B	Raised
Aug 4, 2025	Capital Expenditures	FY2025	$160.00M	New
Aug 4, 2025	Comparable growth	FY2025	+9% – +13%	New
Aug 4, 2025	EPS growth outlook	FY2025	+16% – +20%	New
Aug 4, 2025	EPS outlook	FY2025	$12.40 – $12.76	New
Aug 4, 2025	Free Cash Flow (% of Net Income)	FY2025	80% – 85%	New
Aug 4, 2025	reported operating margin	FY2025	31.3% – 31.6%	New
Aug 4, 2025	Share-based compensation tax rate benefit	FY2025	1.2%	New
Aug 4, 2025	Effective tax rate	FY2025	21%	Raised
Aug 4, 2025	Reduction in average shares outstanding	FY2025	2% – 3%	Lowered
Aug 4, 2025	Operating Cash Flow (% of Net Income)	FY2025	95% – 105%	Raised
Aug 4, 2025	reported CAG Diagnostics recurring revenue growth	FY2025	+6.5% – +8.7%	New
Aug 4, 2025	CAG Diagnostics recurring revenue organic growth	FY2025	+5.8% – +8%	New
Aug 4, 2025	Net interest expense	FY2025	$42.00M	New
Aug 4, 2025	Share-based compensation tax benefit	FY2025	$15.00M	Lowered
Aug 4, 2025	Share-based compensation EPS impact	FY2025	$0.19	New
Aug 4, 2025	Reported growth	FY2025	+7.7% – +9.7%	New
Aug 4, 2025	organic revenue growth	FY2025	+7% – +9%	New
Aug 4, 2025	Revenue	FY2025	$4.21B – $4.28B	New
May 1, 2025	Comparable growth	FY2025	+8% – +12%	Reaffirmed
May 1, 2025	Reported growth	FY2025	+12% – +17%	Raised
May 1, 2025	EPS	FY2025	$11.93 – $12.43	Raised
May 1, 2025	Operating Margin	FY2025	31.1% – 31.6%	New
May 1, 2025	CAG Diagnostics Recurring Revenue Growth Reported growth	FY2025	+4% – +7%	New
May 1, 2025	CAG Diagnostics recurring revenue organic growth	FY2025	+5% – +8%	New
May 1, 2025	Organic growth	FY2025	+6% – +9%	Reaffirmed
May 1, 2025	Reported growth	FY2025	+5% – +8%	Raised
May 1, 2025	Revenue	FY2025	$4.10B – $4.21B	New
Feb 3, 2025	Capital Expenditures	FY2025	$160.00M	New
Feb 3, 2025	Comparable growth	FY2025	+8% – +12%	New
Feb 3, 2025	Reported growth	FY2025	+10% – +15%	New
Feb 3, 2025	EPS	FY2025	$11.74 – $12.24	New
Feb 3, 2025	Operating Margin	FY2025	31% – 31.5%	New
Feb 3, 2025	Effective tax rate	FY2025	21.5%	New
Feb 3, 2025	Net interest expense	FY2025	$42.00M	New
Feb 3, 2025	Revenue	FY2025	$4.06B – $4.17B	New
Feb 3, 2025	CAG Diagnostics Recurring Revenue Growth Reported growth	FY2025	+3% – +6%	Lowered
Feb 3, 2025	Reported growth	FY2025	+4% – +7%	New
Feb 3, 2025	Organic growth	FY2025	+6% – +9%	New
Oct 31, 2024	Capital Expenditures	FY2024	$160.00M	Lowered
Oct 31, 2024	Comparable growth	FY2024	+10% – +11%	Narrowed
Oct 31, 2024	Reported growth	FY2024	+3% – +5%	New
Oct 31, 2024	EPS	FY2024	$10.37 – $10.53	Narrowed
Oct 31, 2024	Free Cash Flow (% of Net Income)	FY2024	90% – 95%	Reaffirmed
Oct 31, 2024	Operating Margin	FY2024	28.7% – 29%	Reaffirmed
Oct 31, 2024	Share-based compensation tax rate benefit	FY2024	1%	New
Oct 31, 2024	Effective tax rate	FY2024	20.7%	Raised
Oct 31, 2024	Reduction in average shares outstanding	FY2024	0.5% – 1%	Lowered
Oct 31, 2024	Operating Cash Flow (% of Net Income)	FY2024	110% – 115%	Raised
Oct 31, 2024	Net interest expense	FY2024	$19.00M	New
Oct 31, 2024	Share-based compensation tax benefit	FY2024	$9.00M	Lowered
Oct 31, 2024	Share-based compensation EPS impact	FY2024	$0.11	New
Oct 31, 2024	Reported growth	FY2024	+5.5% – +6.2%	New
Oct 31, 2024	CAG Diagnostics Recurring Revenue Growth Reported growth	FY2024	+5.6% – +6.2%	Raised
Oct 31, 2024	Organic growth	FY2024	+5.3% – +6%	Lowered
Oct 31, 2024	Revenue	FY2024	$3.87B – $3.89B	New
Oct 31, 2024	CAG Diagnostics Recurring Revenue Growth Organic growth	FY2024	+5.8% – +6.4%	Raised
Aug 6, 2024	Capital Expenditures	FY2024	$180.00M	Reaffirmed
Aug 6, 2024	Comparable growth	FY2024	+9% – +12%	Lowered
Aug 6, 2024	EPS	FY2024	$10.31 – $10.59	Lowered
Aug 6, 2024	Free Cash Flow (% of Net Income)	FY2024	90% – 95%	Reaffirmed
Aug 6, 2024	Operating Margin	FY2024	28.7% – 29%	Lowered
Aug 6, 2024	Organic growth	FY2024	+6.2% – +7.8%	Lowered
Aug 6, 2024	Revenue	FY2024	$3.89B – $3.95B	Lowered
May 1, 2024	Capital Expenditures	FY2024	$180.00M	New
May 1, 2024	comparable basis	FY2024	+9% – +13%	Raised
May 1, 2024	EPS outlook	FY2024	$10.82 – $11.20	Lowered
May 1, 2024	Free Cash Flow (% of Net Income)	FY2024	90% – 95%	Reaffirmed
May 1, 2024	reported operating margin outlook	FY2024	30.2% – 30.7%	Reaffirmed
May 1, 2024	organic	FY2024	+7% – +9%	Lowered
May 1, 2024	revenue guidance	FY2024	$3.90B – $3.97B	Lowered
Feb 5, 2024	Capital Expenditures	FY2024	$180.00M	New
Feb 5, 2024	Comparable growth	FY2024	+8% – +13%	New
Feb 5, 2024	EPS	FY2024	$10.84 – $11.33	New
Feb 5, 2024	Free Cash Flow	FY2024	90% – 95%	New
Feb 5, 2024	Operating Margin	FY2024	30.2% – 30.7%	New
Feb 5, 2024	revenue	FY2024	$3.93B – $4.04B	New
Feb 5, 2024	Organic growth	FY2024	+7% – +10%	New
Nov 1, 2023	capital expenditures	FY2023	$160.00M – $180.00M	New
Nov 1, 2023	comparable basis	FY2023	+25% – +27%	Raised
Nov 1, 2023	EPS outlook	FY2023	$9.74 – $9.90	Raised
Nov 1, 2023	Free Cash Flow	FY2023	85% – 90%	Raised
Nov 1, 2023	operating margin outlook	FY2023	29.6% – 29.8%	Raised
Nov 1, 2023	organically	FY2023	+8.3% – +8.8%	Lowered
Nov 1, 2023	revenue guidance	FY2023	$3.64B – $3.65B	Lowered
Aug 1, 2023	Capital Expenditures	FY2023	$180.00M	Reaffirmed
Aug 1, 2023	Comparable growth	FY2023	+24% – +27%	Raised
Aug 1, 2023	EPS	FY2023	$9.64 – $9.90	Raised
Aug 1, 2023	Operating Margin	FY2023	29.3% – 29.7%	Raised
Aug 1, 2023	Organic growth	FY2023	+8.5% – +10%	Raised
Aug 1, 2023	Revenue	FY2023	$3.66B – $3.72B	Raised
May 2, 2023	capital expenditures	FY2023	$180.00M	Reaffirmed
May 2, 2023	EPS outlook	FY2023	+20% – +26%	Raised
May 2, 2023	EPS outlook	FY2023	$9.33 – $9.75	Raised
May 2, 2023	reported operating margin outlook	FY2023	29% – 29.5%	Lowered
May 2, 2023	revenue growth outlook	FY2023	+7.5% – +10%	Raised
May 2, 2023	revenue guidance	FY2023	$3.62B – $3.70B	Raised
Feb 6, 2023	Capital Expenditures	FY2023	$180.00M	New
Feb 6, 2023	comparable basis	FY2023	+19% – +26%	New
Feb 6, 2023	EPS	FY2023	$9.27 – $9.75	New
Feb 6, 2023	Free Cash Flow	FY2023	80% – 90%	New
Feb 6, 2023	Operating Margin	FY2023	29% – 29.6%	New
Feb 6, 2023	organic growth	FY2023	+7% – +10%	New
Feb 6, 2023	revenue	FY2023	$3.59B – $3.69B	New
Nov 1, 2022	Capital Expenditures	FY2022	$165.00M	Lowered
Nov 1, 2022	Comparable growth	FY2022	-4% – -1%	Lowered
Nov 1, 2022	EPS	FY2022	$7.74 – $7.98	Lowered
Nov 1, 2022	Free Cash Flow	FY2022	60% – 65%	Lowered
Nov 1, 2022	Operating Margin	FY2022	26.3% – 26.8%	Lowered
Nov 1, 2022	Organic growth	FY2022	+6.5% – +7.5%	Narrowed
Nov 1, 2022	Revenue	FY2022	$3.33B – $3.37B	Narrowed
Aug 2, 2022	capital expenditures	FY2022	$180.00M	Reaffirmed
Aug 2, 2022	EPS	FY2022	$7.77 – $8.05	Lowered
Aug 2, 2022	Free Cash Flow	FY2022	65% – 70%	Reaffirmed
Aug 2, 2022	operating margins	FY2022	26.4% – 26.9%	Lowered
Aug 2, 2022	organic revenue growth	FY2022	+5.5% – +8%	Lowered
Aug 2, 2022	Revenue	FY2022	$3.31B – $3.39B	Lowered
May 4, 2022	Capital Expenditures	FY2022	$180.00M	New
May 4, 2022	Comparable growth	FY2022	-1% – +2%	Lowered
May 4, 2022	EPS	FY2022	$8.11 – $8.35	Lowered
May 4, 2022	Free Cash Flow	FY2022	65% – 70%	Lowered
May 4, 2022	operating margins	FY2022	26.8% – 27.3%	Lowered
May 4, 2022	organic	FY2022	+7.5% – +10%	Lowered
May 4, 2022	Revenue	FY2022	$3.39B – $3.47B	Lowered
Feb 2, 2022	capital expenditures	FY2022	$180.00M	New
Feb 2, 2022	comparable basis	FY2022	+12% – +16%	New
Feb 2, 2022	EPS	FY2022	$9.27 – $9.59	New
Feb 2, 2022	Free Cash Flow	FY2022	75% – 80%	New
Feb 2, 2022	Operating Margin	FY2022	29.7% – 30.2%	New
Feb 2, 2022	organic growth	FY2022	+10% – +12%	New
Feb 2, 2022	Revenue	FY2022	$3.50B – $3.57B	New
Nov 2, 2021	Capital Expenditures	FY2021	$150.00M	New
Nov 2, 2021	Comparable growth	FY2021	+26% – +27%	New
Nov 2, 2021	EPS	FY2021	$8.30 – $8.38	New
Nov 2, 2021	Free Cash Flow	FY2021	80% – 85%	New
Nov 2, 2021	Operating Margin	FY2021	28.8% – 29%	New
Nov 2, 2021	Organic growth	FY2021	+15.5% – +16%	New
Nov 2, 2021	Revenue	FY2021	$3.19B – $3.20B	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases IDEXX Laboratories filed with the SEC as exhibits to Form 8-K or 6-K

Aug 4, 2026
Laboratories Announces Second Quarter Results
Results
May 5, 2026
Achieves first quarter revenue growth of 14% as reported and 11% organic, and CAG Diagnostics recurring revenue growth of 14% as
Results
Feb 2, 2026
and Full Year 2025 Results
Results
Jan 13, 2026
Michael Erickson, PhD, to Succeed Jay Mazelsky
Update
Nov 3, 2025
IDEXX Laboratories Announces Third Quarter Results
Results
Aug 4, 2025
John Ravis, Investor Relations, 1-207-556-8155
Results
May 1, 2025
John Ravis, Investor Relations, 1-207-556-8155
Results
Feb 3, 2025
John Ravis, Investor Relations, 1-207-556-8155
Results
Dec 9, 2024
IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization
News
Nov 21, 2024
Brian McKeon to Retire from IDEXX in June 2025
Update
Oct 31, 2024
John Ravis, Investor Relations, 1-207-556-8155
Results
Oct 31, 2024
John Ravis, Investor Relations, 1-207-556-8155
Results
Aug 6, 2024
second quarter revenue growth of 6% as reported and 7% organic, supported by CAG Diagnostics
Results
May 1, 2024
first quarter revenue growth of 7% as reported and organic, supported by CAG Diagnostics
Results
Feb 5, 2024
IDEXX Announces Fourth Quarter and Full Year Results
Results
Nov 1, 2023
IDEXX Laboratories Announces Third Quarter Results
Results
Aug 1, 2023
IDEXX Laboratories Announces Second Quarter Results
Results
May 2, 2023
IDEXX Laboratories Announces First Quarter Results
Results
Feb 6, 2023
IDEXX Laboratories Announces Fourth Quarter and Full Year 2022 Results
Results
Nov 1, 2022
IDEXX Laboratories Announces Third Quarter Results
Results
Aug 2, 2022
IDEXX Laboratories Announces Second Quarter
Results
May 4, 2022
IDEXX Laboratories Announces First Quarter Results
Results
Feb 2, 2022
IDEXX Laboratories Announces Fourth Quarter
Results
Nov 2, 2021
IDEXX Laboratories Announces Third Quarter Results
Results

Where these numbers come from

Parsed from the XBRL in IDEXX Laboratories's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jun 16, 2015
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IDXX.

Compare: IDXX vs QDEL · IDXX vs NEOG · IDXX vs ELAN · IDXX vs LNTH · IDXX vs ZTS

Revenue growth12.8% · median 1.5%

Gross margin62.4% · median 55.4%

Operating margin32.0% · median -0.8%

Net margin25.0% · median -4.0%

Company	Revenue	Growth
ZTS	$9.52B	+1.5%
ELAN	$5.02B	+12.0%
IDXX	$4.55B	+12.8%
QDEL	$2.67B	-2.5%
LNTH	$1.56B	+2.3%
NEOG	$883.99M	-0.3%

Company

Next earnings (est.): Nov 2, 2026, before open
Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
Fiscal year ends: December 31
Employees: 11,000
Held by institutions: 94.5%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 874716

Advertisement
300 × 250